{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:59:43Z","timestamp":1780898383935,"version":"3.54.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radical cystectomy remains a standard curative treatment for muscle-invasive bladder cancer (MIBC). Bladder preservation after systemic therapy without immediate surgery remains investigational and requires careful patient selection, rigorous reassessment, and structured surveillance. We report two cases of early tumor regression after limited-course immunotherapy-based systemic therapy, with bladder-intact survival during available follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Two male patients aged 75 and 73 years with clinically staged bulky bladder tumors suspicious for MIBC (one cT3N0M0 and the other at least cT2N0M0) received limited-course PD-1 inhibitor-based systemic therapy without immediate radical cystectomy. Both patients showed marked regression after two treatment cycles: Case 1 received tislelizumab plus platinum-based chemotherapy, and Case 2 received toripalimab plus disitamab vedotin. In Case 2, post-treatment transurethral reassessment and multi-site biopsies showed no definite residual malignancy; one additional cycle was then administered. Radical cystectomy was recommended but declined in both cases. At approximately three years after treatment initiation, no clinically detectable recurrence was identified based on available, non-protocolized assessments, although interval cystoscopic surveillance was incomplete.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These cases document unusually early regression after limited-course immunotherapy-based systemic therapy in clinically staged bulky bladder tumors. The findings remain hypothesis-generating and do not justify routine omission of radical cystectomy or abbreviated systemic therapy. Instead, they suggest that early response kinetics may identify exceptional responders who warrant rigorous multimodal reassessment, molecular characterization, and structured surveillance within future response-adapted bladder-preserving strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1866469","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:33:38Z","timestamp":1780896818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Su","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Lanzhou University Second Hospital","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanghao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cuiying Honors College, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Urology, Gannan Tibetan Autonomous Prefecture People\u2019s Hospital","place":["Hezuo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Urology, Gannan Tibetan Autonomous Prefecture People\u2019s Hospital","place":["Hezuo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, Gannan Tibetan Autonomous Prefecture People\u2019s Hospital","place":["Hezuo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Urology, Lanzhou University Second Hospital","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Lanzhou University Second Hospital","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Gannan Tibetan Autonomous Prefecture People\u2019s Hospital","place":["Hezuo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18060961","article-title":"Bladder preservation with concurrent chemoradiotherapy following complete response to induction systemic therapy in patients with muscle-invasive bladder cancer: A review of the existing literature","volume":"18","author":"Ntoumas","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01211-1","article-title":"Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study","volume":"10","author":"Guo","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1186\/s12885-025-14154-4","article-title":"RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1866469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:33:41Z","timestamp":1780896821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1866469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2026.1866469"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1866469","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1866469"}}